Price T Rowe Associates Inc. MD Cuts Stock Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Price T Rowe Associates Inc. MD lowered its stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 94.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 32,548 shares of the company's stock after selling 592,930 shares during the quarter. Price T Rowe Associates Inc. MD's holdings in Neumora Therapeutics were worth $346,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in Neumora Therapeutics by 4.5% in the fourth quarter. Vanguard Group Inc. now owns 4,572,308 shares of the company's stock worth $48,466,000 after purchasing an additional 195,142 shares during the period. Capital International Investors grew its holdings in shares of Neumora Therapeutics by 692.1% during the fourth quarter. Capital International Investors now owns 3,700,359 shares of the company's stock valued at $39,224,000 after buying an additional 3,233,179 shares during the last quarter. Rock Springs Capital Management LP raised its position in Neumora Therapeutics by 15.3% in the fourth quarter. Rock Springs Capital Management LP now owns 955,106 shares of the company's stock worth $10,124,000 after acquiring an additional 127,005 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Neumora Therapeutics by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 704,154 shares of the company's stock valued at $7,464,000 after purchasing an additional 5,899 shares in the last quarter. Finally, Barclays PLC boosted its position in shares of Neumora Therapeutics by 29.1% in the fourth quarter. Barclays PLC now owns 166,822 shares of the company's stock worth $1,767,000 after purchasing an additional 37,612 shares during the period. Hedge funds and other institutional investors own 47.65% of the company's stock.

Wall Street Analyst Weigh In

NMRA has been the topic of several recent analyst reports. Guggenheim downgraded shares of Neumora Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday, March 7th. Stifel Nicolaus downgraded shares of Neumora Therapeutics from a "buy" rating to a "hold" rating and reduced their target price for the stock from $6.00 to $2.00 in a report on Friday, March 7th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $4.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. HC Wainwright dropped their price target on shares of Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Finally, Bank of America reaffirmed an "underperform" rating and set a $1.00 price target (down from $7.00) on shares of Neumora Therapeutics in a research note on Wednesday, April 2nd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $9.29.

Neumora Therapeutics Stock Up 2.1%

Shares of NASDAQ:NMRA traded up $0.01 during trading on Tuesday, hitting $0.71. The stock had a trading volume of 33,310 shares, compared to its average volume of 1,501,418. Neumora Therapeutics, Inc. has a 12-month low of $0.61 and a 12-month high of $17.19. The stock has a 50-day simple moving average of $0.83 and a two-hundred day simple moving average of $4.17. The stock has a market capitalization of $114.03 million, a price-to-earnings ratio of -0.38 and a beta of 2.96.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.02). As a group, sell-side analysts forecast that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current year.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.